Trial Profile

A phase IV post-marketing study of OFEV for the treatment of idiopathic pulmonary fibrosis (IPF)

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 25 Nov 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nintedanib (Primary)
Indications Idiopathic pulmonary fibrosis
Focus Adverse reactions

Most Recent Events

25 Nov 2015 New trial record
13 Nov 2015 According to a Boehringer Ingelheim media release, results from this study will be presented at the Pulmonary Fibrosis Foundation's PFF Summit 2015.
13 Nov 2015 Results published in a Boehringer Ingelheim media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com